Data-crunching specialist CytoReason signs $110m Pfizer alliance
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal
Pfizer to further tap CytoReason’s AI technology for drug discovery in up to $110M deal
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Bringing Data to Life – Joint Webinar about CytoReason-Ferring Collaboration
CytoReason expands reach in Asia, leveraging ML in drug development for Korean drugmakers
Israel’s CytoReason, S. Korea’s Helixrus partner on machine learning for drug development
Poolbeg signs deal with Cytoreason on influenza drug development
Poolbeg Pharma signs first of its kind AI deal with CytoReason
Pfizer, CytoReason extend AI pact after immune system success
